Published in final edited form as:

Chem Commun (Camb). 2015 November 19; 51(96): 17072–17075. doi:10.1039/c5cc06858d.

Highly-Efficient and Versatile Fluorous-Tagged Cu(I)-Catalyzed Azide-Alkyne Cycloaddition Ligand for Preparing Bioconjugates

Lingyi Sun^{a,†}, Yongkang Gai^{a,†}, Carolyn J. Anderson^a, and Dexing Zeng^a

Dexing Zeng: zengd@upmc.edu

^aDepartment of Radiology, University of Pittsburgh, 100 Technology Drive, Pittsburgh, PA 15219, USA

Abstract

A novel ligand (FBTTBE) for Cu(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) has been developed, which demonstrates not only superior catalytic efficiency but also the ease of removing toxic copper species. FBTTBE has also been successfully applied in the synthesis of radiometal-labeled peptide and antibody without observable transchelation with the non-radioactive Cu(I) catalyst.

Click chemistry, particularly the copper(I)-catalyzed azide alkyne cycloaddition (CuAAC)¹, has found applications in a wide range of modern chemistry-related areas, including organic chemistry, drug discovery, drug delivery and chemical biology.^{2–6} However, the toxicity of copper(I) from the generation of reactive nitrogen and oxygen species⁷ limits its application in living systems.^{8,9} For example, upon treatment of 1 mM CuSO₄, 1.5 mM sodium ascorbate, and 0.1 mM TBTA (Figure 1), Zebrafish embryos do not survive beyond 15 min.¹⁰ Therefore, the removal of copper species is typically required in order to avoid cytotoxicity caused by residual copper ions in biological applications, adding another layer of complexity to the application of CuAAC in living systems. To overcome the cumbersome copper removal problem, major efforts have been made to minimize the risk caused by this metal catalyst. New methodologies and techniques have been developed, including copper-free variants of azide-alkyne click chemistry (e.g., strain-promoted azide-alkyne cycloaddition (SPAAC) and resin-supported catalyst systems).^{11–14} However, these strategies cannot fulfill all the requirements due to their inherent deficiencies, including relatively sluggish kinetics in SPAAC and copper leaching problems observed in the resin-supported catalyst systems.¹⁵ Therefore, a more efficient approach is highly desired.

Here we report the development of a novel fluorous tagged tris(triazolylmethyl)amine-based Cu(I) stabilizing ligand (FBTTBE; Figure 1). This ligand has great promise towards facilitating the removal of toxic catalytic species while maintaining high catalytic efficiency. The use of a fluorous tag enables the easy separation of the toxic catalyst from the product

Correspondence to: Dexing Zeng, zengd@upmc.edu.

[†]These authors contributed equally.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here].
See DOI: 10.1039/x0xx00000x

(non-fluorous species) via the Fluorous Solid-Phase Extraction (F-SPE) approach¹⁶, whereby the separation is accomplished by simply passing the reaction mixture through a fluorous silica gel. The bis(tert-butyltriazolyl) methyl amine based catalytic core shows significantly improved kinetics compared with two commercially available Cu(I) ligands, TBTA and THPTA (Figure 1).¹⁷ This new design of the catalytic ligand integrates homogenous solution phase reaction conditions with a phase-tag separation, while maintaining high reactivity as well as strong capacity to fully complex the copper ions. It is believed that the synergy of the fluorous-tag and the catalytic core in the designed FBTTBE ligand will result in much broader applications of CuAAC. The linker between the fluorous tag and catalytic core provides the necessary distance to reduce possible steric effects, and in the future it can be replaced by a PEGylated linker to counter the loss of hydrophilic groups (i.e., the hydroxyl in THPTA) for improved aqueous solubility.

In our study, a model FBTTBE ligand was synthesized *via* multiple steps (Scheme 1). Alcohol **1** was treated with sodium azide to generate azide **2**. Subsequently, **2** was reacted with 3,3-diethoxy-1-propyne through a copper catalyzed click reaction to give the corresponding triazole **3**, which was then converted to the triazolylcarbaldehyde **4** *via* TFA (trifluoroacetic acid) treatment. Facilitated by the reduction reagent NaBH(OAc)₃, intermediate **5** was then prepared through the reaction between **4** and propargyl amine.¹⁸ Intermediate **7** was synthesized by treating the alcohol **6** first with thionyl chloride, followed by azidation using sodium azide. In the final step, the FBTTBE ligand **8** was obtained through the click reaction between **5** and **7**.

As discussed above, the fluorous-tag containing FBTTBE ligand features a rapid F-SPE removal capability. Utilizing radioactive ⁶⁴Cu²⁺, the trapping efficiency of the fluorous silica gel was determined. In this experiment, ⁶⁴Cu²⁺ (100 μ Ci) was added to a non-radioactive Cu²⁺ solution, and the resulting carrier-added ⁶⁴Cu²⁺ (200 μ M) was then mixed with 1.5 equiv. of FBTTBE followed by 1.0 eq. of NaAA; the mixture was passed through the fluorous silica gel after a 5 min incubation. Over 99% of the radioactivity remained on silica gel demonstrating that FBTTBE-Cu(I) can be efficiently trapped. Therefore, it is anticipated that the removal of toxic copper species after CuAAC can be greatly simplified to a one-step filtration using FBTTBE as the catalytic ligand.

In order to investigate its catalytic efficiency, the reactivity of the synthesized FBTTBE ligand was then compared with two widely used ligands TBTA and THPTA. Specifically, we compared the relative reactivity of the canonical Cu(I) catalysts in the form of TBTA-Cu(I), THPTA-Cu(I) and FBTTBE-Cu(I) *via* a reported fluorogenic assay¹⁷ based on the reaction between propargyl amine and 3-azido-7-hydroxycoumarin (Scheme S1). Upon formation of the triazole ring, strong fluorescence at 477 nm can be quantitatively measured to determine the extent of the reaction. FBTTBE showed the greatest ability to accelerate CuAAC, followed by THPTA, with TBTA having the lowest reactivity (Figure 2). The reaction catalyzed by Cu(I)-FBTTBE completed in around 20 min at ambient temperature using 10 μ M of Cu(I) and 1.5 eq. (15 μ M) of FBTTBE. In contrast, no more than 40% yield was achieved after 12 h with the TBTA and THPTA ligands. This implies that FBTTBE renders a much higher catalytic capacity in CuAAC compared with TBTA and THPTA. The catalytic efficiency of the non-fluorous tagged analogue BTTBE was found to be higher than

that of FBTTBE (Figure S1), indicating the fluororous tag will affect the reactivity of the catalytic core. This decreasing of catalytic efficiency could be reversed by adding excess amount of FBTTBE which could be conveniently removed by the fluororous silica gel after the reaction.

The superior catalytic efficiency as well as the ease of separating toxic copper species when using FBTTBE drove us to further investigate its application in preparing agents that could be used in living systems, such as a fluorescent dye attached peptide for fluorescent microscopy staining. Specifically, CuAAC between Cy3-azide and acetylene-AE105 (aurokinase-type plasminogen activator receptor, uPAR-targeted peptidic ligand) catalyzed by various Cu(I)-ligands was compared (Figure S2). The Cu(I)-FBTTBE catalyzed CuAAC was complete in 5 min, whereas neither Cu(I)-TBTA nor Cu(I)-THPTA could achieve over 50% yield, even after incubating for 8 h. More importantly, both the Cu(I)-FBTTBE catalyst and excess FBTTBE ligand were rapidly removed by F-SPE. The resulting Cy3-AE105 conjugate was then used to stain human U87MG glioblastoma cells that overexpress uPAR (Figure 3).

In addition to the rapid and complete removal of toxic copper species and excellent catalytic efficiency, the FBTTBE catalyst also demonstrated the capability of minimizing transchelation between non-radioactive copper and radiometals. In 2006, Marik and Sutcliffe reported the first use of this method in preparing [^{18}F]fluoropeptides,¹⁹ and since then a large body of work employing the CuAAC has been presented in the preparation of ^{18}F -based PET radiotracers.²⁰ However, its application in radiometal-based probes still remains noticeably underdeveloped, possibly attributed to the transchelation between non-radioactive copper ions and those radiometals.^{21–25} Even with an extremely low concentration of radiometal-containing reactants (e.g., 10–100 nM) and rapid decay of these radionuclides, a relatively large amount of the catalyst is required to ensure that the pmol-reactant reaction can complete within a relatively short time. This leads to not only difficulty in catalyst removal but also significant radiometal transchelation, resulting in significant decreases in specific activity of the corresponding radiopharmaceuticals.¹⁷

Here, a click reaction used for preparing the ^{64}Cu -labeled peptide was employed to evaluate the performance of FBTTBE in addressing both removal of toxic copper and the radiometal transchelation problems. Specifically, azide modified CB-TE1K1P chelator ($\text{N}_3\text{-CB-TE1K1P}$)²⁶ was incubated with ^{64}Cu for 5 min at 90 °C, and the resulting $\text{N}_3\text{-(}^{64}\text{Cu)}\text{CB-TE1K1P}$ chelate was then conjugated to acetylene-AE105 peptide via CuAAC catalyzed by different ligands (Scheme S2). FBTTBE exhibited much higher catalytic efficacy than either TBTA or THPTA (Figure S3). The rapid F-SPE removal capability was then investigated by comparing the UV peaks in the two HPLC traces of the above CuAAC mixtures before and after F-SPE purification. The retention time of the FBTTBE/FBTTBE-Cu(I) appeared to be 22.3 min according to the HPLC trace of the CuAAC mixture before F-SPE purification (Figure 4A). After the F-SPE purification, it was found that the UV peak representing the FBTTBE/FBTTBE-Cu(I) completely disappeared (Figure 4B), indicating that the catalyst was completely removed by the fluororous silica gel. In addition, the reaction mixture was also analyzed by the radio-HPLC to monitor potential transchelation. It was found that the radio-purity of the final product (retention time = 20 min, Figure 4A) was >98%, while there

was no radioactive peak at either 1.5 or 22.3 min for Cu ions and FBTBTE-Cu(I), respectively. Therefore, FBTBTE can be regarded as an excellent ligand for the preparation of radiometal-based radiopharmaceuticals. The resulting (^{64}Cu)CB-TE1K1P-AE105 was subsequently used for PET/CT imaging of nude mice bearing subcutaneous U87MG xenografts that overexpress uPAR (Figure 5).

The FBTBTE ligand has also been successfully applied in the rapid radiometal labeling of antibodies. Proteins are typically more sensitive to radiolabeling conditions such as pH, temperature and incubation time than small molecules and peptides. As a proof-of concept study, a monoclonal anti-EGFR antibody (cetuximab) was functionalized with an acetylene group using a slightly modified procedure from what was previously reported.²⁷ The resulting acetylene-cetuximab was conjugated with N_3 -(^{64}Cu)CB-TE1K1P *via* the Cu(I)-FBTBTE catalyzed CuAAC under mild conditions (37 °C for 30 min) that would not denature the protein. The results were encouraging in that 50% of the (^{64}Cu)CB-TE1K1P was attached to cetuximab. The specific activity of the resulting ^{64}Cu -labeled cetuximab was 10 $\mu\text{Ci}/\mu\text{g}$ after purification by a Zeba desalting column. Together, these data demonstrated the broad applicability of the Cu(I)-FBTBTE catalyst for radiometal labeling of peptides and antibodies.

In summary, a novel CuAAC ligand FBTBTE has been successfully developed that not only demonstrated higher catalytic efficiency than two commercial available ligands (TBTA & THPTA), but also simplified the removal of toxic copper species after reactions, rendering it an ideal ligand for CuAAC. In addition, transchelation was avoided when applying FBTBTE in preparing radiometal-based pharmaceuticals, broadening the application of CuAAC beyond ^{18}F -chemistry. Although reactions presented here are primarily geared toward PET and molecular imaging, FBTBTE can be applied in almost any CuAAC where the high reaction rate as well as the complete removal of copper species are desired.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Sai Zhao for his assistance with the synthesis and fluorogenic assay. This work was supported by the National Institute of Biomedical Imaging and Bioengineering grant R21-EB017317. Preclinical PET/CT imaging is supported in part by P30CA047904 (UPCI CCSG).

References

1. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem Int Edit.* 2002; 41:2596–2599.
2. Hein JE, Fokin VV. *Chem Soc Rev.* 2010; 39:1302–1315. [PubMed: 20309487]
3. Kolb HC, Finn MG, Sharpless KB. *Angew Chem Int Edit.* 2001; 40:2004–2021.
4. Kolb HC, Sharpless KB. *Drug Discov Today.* 2003; 8:1128–1137. [PubMed: 14678739]
5. Lallana E, Sousa-Herves A, Fernandez-Trillo F, Riguera R, Fernandez-Megia E. *Pharm Res.* 2012; 29:1–34. [PubMed: 21913032]
6. Spicer CD, Davis BG. *Nat Commun.* 2014; 5
7. Gaetke LM, Chow CK. *Toxicology.* 2003; 189:147–163. [PubMed: 12821289]
8. Link AJ, Tirrell DA. *J Am Chem Soc.* 2003; 125:11164–11165. [PubMed: 16220915]

9. Speers AE, Adam GC, Cravatt BF. *J Am Chem Soc.* 2003; 125:4686–4687. [PubMed: 12696868]
10. Sletten EM, Bertozzi CR. *Angew Chem Int Edit.* 2009; 48:6974–6998.
11. Carpenter RD, Hausner SH, Sutcliffe JL. *ACS Med Chem Lett.* 2011; 2:885–889. [PubMed: 24900276]
12. Blackman ML, Royzen M, Fox JM. *J Am Chem Soc.* 2008; 130:13518–13519. [PubMed: 18798613]
13. Presolski SI, Mamidyala SK, Manzenrieder F, Finn MG. *ACS Comb Sci.* 2012; 14:527–530. [PubMed: 22946559]
14. Gao Z, Gouverneur V, Davis BG. *J Am Chem Soc.* 2013; 135:13612–13615. [PubMed: 23991754]
15. de Almeida G, Sletten EM, Nakamura H, Palaniappan KK, Bertozzi CR. *Angew Chem Int Edit.* 2012; 51:2443–2447.
16. Zhang W. *Chem Rev.* 2004; 104:2531–2556. [PubMed: 15137799]
17. Besanceney-Webler C, Jiang H, Zheng T, Feng L, Soriano del Amo D, Wang W, Klivansky LM, Marlow FL, Liu Y, Wu P. *Angew Chem Int Edit.* 2011; 50:8051–8056.
18. Soriano del Amo D, Wang W, Jiang H, Besanceney C, Yan AC, Levy M, Liu Y, Marlow FL, Wu P. *J Am Chem Soc.* 2013. 2010; 132:16893–16899.
19. Marik J, Sutcliffe JL. *Tetrahedron Lett.* 2006; 47:6681–6684.
20. Zeng D, Zeglis BM, Lewis JS, Anderson CJ. *J Nucl Med.* 2013; 54:829–832. [PubMed: 23616581]
21. Kumar V, Boddeti DK. *Recent Res Cancer.* 2013; 194:189–219.
22. Anderson CJ, Ferdani R. *Cancer Biother Radio.* 2009; 24:379–393.
23. Verel I, Visser GW, Boellaard R, Stigter van Walsum M, Snow GB, van Dongen GA. *J Nucl Med.* 2003; 44:1271–1281. [PubMed: 12902418]
24. Willowson K, Forwood N, Jakoby BW, Smith AM, Bailey DL. *Med Phys.* 2012; 39:7153–7159. [PubMed: 23127106]
25. Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, et al. *Life Sci.* 1991; 49:1583–1591. [PubMed: 1658515]
26. Zeng D, Ouyang Q, Cai Z, Xie XQ, Anderson CJ. *Chem Com.* 2014; 50:43–45.
27. Zeng D, Guo Y, White AG, Cai Z, Modi J, Ferdani R, Anderson CJ. *Mol Pharm.* 2014; 11:3980–3987. [PubMed: 24720806]

Figure 1.
FBTTB, TBTA and THPTA.

Figure 2. Comparison of Cu(I) stabilizing ligands in the CuAAC between propargyl amine and 3-azido-7-hydroxycoumarin ([azidocoumarin] = 10 μ M; [propargyl amine] = 15 μ M, ligand : Cu(I) = 1.5 : 1).

Figure 3.
Microscopy staining of U87MG cells with A) Cy3-AE105; and B) Cy3-AE105 with blocking (be more specific).

Figure 4.

HPLC results: A) N_3 -CB-TE1K1P(64 Cu) click reaction with acetylene-AE105 catalyzed by 1.0 eq. of FBTBTE; B) Spectrum after the fluorous-silica gel purification of the reaction mixture.

Figure 5.
PET/CT imaging of mice bearing U87MG xenografts: A) 1 h p.i.; B) 4 h p.i.; c) with blockade, 4 h p.i.

Scheme 1.

Synthesis of the FBTTBE ligand. Reagents and conditions: (a) NaN₃, H₂SO₄: H₂O = 1:1 (w/w); (b) 3,3-diethoxy-1-propyne, NaHCO₃, CuSO₄, sodium ascorbate (NaAA), t-BuOH : H₂O = 1:1 (v/v); (c) TFA, DCM : H₂O = 2:1 (v/v); (d) propargyl amine, NaBH(OAc)₃, Dichloroethane; (e) 1). SOCl₂, DMF, 2). NaN₃, DMF: THF = 1:1 (v/v); (f) CuSO₄, NaAA, t-BuOH : H₂O = 1:1 (v/v).